PRECIGEN pipeline
Discovery
by Design
Our growing pipeline of multifunctional gene and cell therapy candidates gives us distinct advantages for combination strategies. Our preclinical and clinical pipeline includes several programs leveraging our technologies in core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
Clinical Pipeline
As of January 7, 2024
| Product | Platform | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
| PRGN-2012 | OTS AdenoVerse Immunotherapy | RRP | |||||
| PRGN-2009+pembrolizumab | OTS AdenoVerse Immunotherapy | OPSCC | |||||
| PRGN-2009+pembrolizumab | OTS AdenoVerse Immunotherapy | R/M Cervical Cancer | |||||
| PRGN-3006 | UltraCAR-T | AML, MDS | |||||
| PRGN-3005 | UltraCAR-T | Ovarian Cancer | |||||
| PRGN-3007 | UltraCAR-T | Hematological & Solid Tumors | |||||
| AG019 | ActoBiotics | Type 1 Diabetes |
Expanded Access Policy
Download PolicyFor physicians seeking pre-approval access to one of our investigational therapies, please review our expanded access policy. For expanded access inquiries, please contact us at expandedaccess@precigen.com.